Our Vision & Experience
For decades, researchers have pursued coding-gene pharmacogenomic testing as a way of improving medication selection and reducing medication side effects. Despite advances, the results have been limited in their ability to predict patient outcomes, interpret drug-drug interactions, and avoid potential adverse reactions.
A University of Michigan team, led by Dr. Brian D. Athey, developed a breakthrough technology for determining how individual genes are impacted by specific drugs, when evaluated in a combination with external environmental factors and patient traits, such as network biology, ethnicity, environment, sociological factors, and recorded health history.
The result is a highly predictive profile of a patient’s unique drug response or phenotype. Athey and biotechnology entrepreneur Dr. James S. Burns evaluated the potential applications of advanced pharmacogenomics and created a plan to move the technology forward. Phenomics Health Inc. (PHI) was launched in 2018 and PHI’s proprietary Precision Phenome Platform™ (P3) was introduced.
Dedicated to commercializing novel pharmacogenomic and precision medicine products and services across therapeutic areas associated with chronic pain, mental illness, stress, and cardiovascular disease.
Phenomics Health provides contract-based and collaborative research services to test mechanisms and pathways for new and repurposed drugs, including CNS, cardiovascular disease, cancer, GI, and immune system disorders.
Patented pharmacogenomic technology, enabled by Artificial Intelligence (AI) and Machine Learning, fuels the precision of Phenomics Health technological breakthroughs.